RxSight Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
RXST$4.540.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Equity
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except number of shares)
| Common stock · Additional paid-in · Accumulated other · Accumulated · Total stockholders' | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount · capital · comprehensive (loss) income · deficit · equity | ||||||||
| Balance at December 31, 2021 | 27,366,746 | $27 | $617,511 | $(20) | $(479,276) | $138,242 | ||
| Shares issued for the exercise of stock options and vesting of restricted stock units | 382,506 | 1 | 840 | — | — | 841 | ||
| Shares redeemed for employee tax withholdings | (49,456) | — | (643) | — | — | (643) | ||
| Stock-based compensation expense | — | — | 11,397 | — | — | 11,397 | ||
| Shares issued for the employee stock purchase plan | 92,718 | — | 937 | — | — | 937 | ||
| Issuance of common stock for at-the-market offerings, net of issuance costs | 475,875 | — | 5,959 | — | — | 5,959 | ||
| Other comprehensive loss | — | — | — | (75) | — | (75) | ||
| Net loss | — | — | — | — | (66,756) | (66,756) | ||
| Balance at December 31, 2022 | 28,268,389 | $28 | $636,001 | $(95) | $(546,032) | $89,902 | ||
| Shares issued for the exercise of stock options and vesting of restricted stock units | 1,103,974 | 1 | 8,351 | — | — | 8,352 | ||
| Shares redeemed for employee tax withholdings | (62,068) | — | (1,423) | — | — | (1,423) | ||
| Stock-based compensation expense | — | — | 15,746 | — | — | 15,746 | ||
| Shares issued for the employee stock purchase plan | 87,129 | — | 1,121 | — | — | 1,121 | ||
| Issuance of common stock for public offering, net of underwriting discounts, commissions and offering costs | 4,600,000 | 5 | 53,595 | — | — | 53,600 | ||
| Issuance of common stock for at-the-market offerings, net of issuance costs | 2,142,089 | 2 | 41,580 | — | — | 41,582 | ||
| Other comprehensive income | — | — | — | 90 | — | 90 | ||
| Net loss | — | — | — | — | (48,608) | (48,608) | ||
| Balance at December 31, 2023 | 36,139,513 | $36 | $754,971 | $(5) | $(594,640) | $160,362 | ||
| Shares issued for the exercise of stock options and vesting of restricted stock units | 2,262,698 | 2 | 19,243 | — | — | 19,245 | ||
| Shares redeemed for employee tax withholdings | (85,814) | — | (4,768) | — | — | (4,768) | ||
| Stock-based compensation expense | — | — | 24,635 | — | — | 24,635 | ||
| Shares issued for the employee stock purchase plan | 58,252 | — | 1,571 | — | — | 1,571 | ||
| Issuance of common stock for public offering, net of underwriting discounts, commissions and offering costs | 2,053,571 | 2 | 107,475 | — | 107,477 | |||
| Other comprehensive income | — | — | — | 171 | — | 171 | ||
| Net loss | — | — | — | — | (27,455) | (27,455) | ||
| Balance at December 31, 2024 | 40,428,220 | $40 | $903,127 | $166 | $(622,095) | $281,238 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.